Date: Thursday, January 20, 2022
Time: 10:00 am - 11:00 am USA Pacific Time (PT);
1:00 pm - 2:00 pm USA Eastern Time (ET); 19:00 h - 20:00 h CEST
Paul Diehl, Ph.D., Chief Operating Officer, Cellecta Inc.
Measurements of changes in gene activation and expression provide a basis to understand genetic changes causing biological responses. Cell-to-cell gene disruption induced by CRISPR and other gene-perturbation technologies help tease out the drivers of these responses. Adaptations of these two screening approaches can be used to discover the genetic drivers responsible for phenotypic variabilities such as drug sensitivities and disease variation across tissue microenvironments, and between single cells. An overview of recent publications illustrating successful use of these methods will be presented.
A brief overview of Cellecta technologies will precede the presentation
Get an overview of recent peer-reviewed publications demonstrating how functional CRISPR screening and other related methods have been used to identify: